ClinicalTrials.gg
Not yet recruitingNCT07017452Updated Jun 12, 2025

Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia

A Phase 3 interventional study of Methoxyflurane - Penthrox and Control in Benign Prostate Hypertrophy(BPH), sponsored by University of Manitoba. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by University of Manitoba · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Prostatic Hyperplasia with a site in Canada — 11 open to participants now, 16 under way, 3 of them phase 3. Prostatic Hyperplasia · Canada.

Planned enrollment
36th of 47
48 · median 108
Started
2025
with 2 others
Phase 3
14 of 53
3 open now
Primary completion
2025-12
later than 8 of 15 live
Registered
51st of 53
by date
Lead sponsor
3 of 53
University of Manitoba

Among the 53 studies in Prostatic Hyperplasia with a site in Canada, this one is the 36th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 8 of the 15 other live ones, and was the 51st registered.

Prostatic Hyperplasia

830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

11 of the 53 studies in Prostatic Hyperplasia with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Prostatic Hyperplasia with a site in Canada, or all of them as a file.
02

Study summary

The primary aim of the study is to show that methoxyflurane-lorazepam-percocet combination administrated 'per os' is non inferior to deep intravenous sedation in achieving analgesia during Rezum convective radiofrequency water vapor thermal therapy for the management of benign prostate hyperplasia (BPH). We propose to conduct a single-centered, unblinded, randomized controlled trial designed after consulting ICH Guidelines for Good Clinical Practice as well the regulations set by the Biomedical Research Ethics Board, University of Manitoba.

Read the detailed description

Participants who belong to the experimental arm will be given a single 'per os' dose of percocet (325mg acetaminophen + 7.5mg oxycodone) and lorazepam 1 mg, 30 minutes prior to the procedure. Patients will receive education on how to use the Penthrox inhaler device. Inside the operating room, the subject would self-inhale the methoxyflurane 5 minutes prior to the procedure. All these steps will be supervised by the clinical research nurse. Each participant will be administered with 3ml of methoxyflurane which is poured into the inhaler. Participants who were randomized to the control arm will receive deep intravenous sedation under the supervision of a trained anesthetist. A combination of midazolam, ketamine, remifentanil and propofol will be administered using an intravenous line. The quantity of these medications will be calculated by the anesthetist based on clinical judgement and also takes into account the physical characteristic of the subject. Both the groups receive the same Rezum water vapor therapy and the number of Rezum injections depends on the clinical judgement of the urologist performing the procedure. Immediately, post the procedure, the self-reported pain of the patient will be recoded using the NRS. A phone call follow-up would be done the following day to record any adverse events caused due to the procedure. Four weeks post the procedure, a phone call follow-up would be done to understand the patient satisfaction after the surgery.

03

Conditions studied

  • Benign Prostate Hypertrophy(BPH)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide an .
  • Age ≥ 18 years
  • Biological males identified with male sexual organs.
  • Scheduled for convective radiofrequency water vapor thermal therapy (REZUM) for the management of benign prostate hyperplasia.

Exclusion criteria

Exclusion Criteria:

  • Concomitant use of nephrotoxic and/or hepatoxic agents.
  • Use of ≥ 6 ml Penthrox withing the previous 3 weeks.
  • Known allergies and/or adverse events due to penthrox, other halogenated anesthetics, percocet (oxycodone + acetaminophen), lorazepam, lidocaine, midazolam, ketamine, remifentanil and propofol
  • History of genetic susceptibility to malignant hyperthermia.
  • Presence of respiratory depression, cardiovascular instability, renal or hepatic impairment
  • Altered level of consciousness due to any cause.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Intervention arm-Penthrox

    Participants can begin using penthrox 10 minutes prior to procedure start, given its median onset time of 5 minutes

    Drug: Methoxyflurane - Penthrox · Drug: Percocet Pill · Drug: Lorazepam (drug)

  • Placebo comparator
    Control arm

    Patients will receive standard of care during their rezum procedure which consists of deep IV sedation.

    Other: Control

Interventions

  • Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.

  • OtherControl

    This intervention will be the control group only, receiving deep IV sedation.

  • DrugPercocet Pill

    Percocet will be given in conjunction with methoxyfluorane and lorazepam

  • Lorazepam will be given in conjunction with penthrox and percocet.

06

What researchers measure

Primary outcomes

  1. Post-Procedural Pain

    Post procedural pain measured using the Numeric Rating Scale for pain. Higher scores on this measurement indicate worser outcomes. Maximum value of 10 and a minimum value of 10 can be reported on this scale.

    Time frame: Immediately post-procedure

Secondary outcomes

  1. Safety of Procedure

    The safety of combination vs deep intravenous sedation during Rezum will be measured by accounting for adverse event encountered during the procedure.

    Time frame: At time of procedure and post-procedure

  2. Cost-effectiveness,

    We will compare the costs associated with the procedure in both arms to see if there is any difference.

    Time frame: 1 month post-procedure

  3. Anxiety levels

    We will measure anxiety levels using the Amsterdam Pre-Operative Anxiety and Information Scale (APAIS). Higher scores indicate worser outcomes. Maximum value of 30 and a minimum value of 0. It is a 6 part questionnaire which each question is given on a likert scale from 1-5

    Time frame: Pre-Procedure on day of procedure

  4. Patient satisfaction

    We will measure patient satisfaction using a likert scale single question patient satisfaction questionnaire. (higher scores indicate better outcomes). Maximum value of 5 and a minimum value of 0.

    Time frame: Immediately post-procedure

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.

Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
Jun 12, 2025
StartEst.
Aug 2025
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07017452
Responsible party
Premal Patel, MD (Assistant Professor, Department of Surgery. Director, Undergraduate Urologic Medical Education, University of Manitoba) — Principal investigator
First posted
Jun 12, 2025
Start date
Aug 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jun 12, 2025

Study contacts

Premal Patel, MD
Contact
ppatel5@hsc.mb.ca
204-221-4476

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorazepam

Start the discussion